Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 7.23% in last session and finished the day at $ … Continue reading Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Active Stocks: Endocyte (NASDAQ:ECYT), Gilead Sciences, Inc. (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA), Immunomedics (NASDAQ:IMMU)

Endocyte (NASDAQ:ECYT)’s shares saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. Endocyte, Inc. (NASDAQ:ECYT) stock performance was 61.91% in last session and finished the day at $ 6.62. Traded volume was 17,639,435 shares in … Continue reading Active Stocks: Endocyte (NASDAQ:ECYT), Gilead Sciences, Inc. (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA), Immunomedics (NASDAQ:IMMU)

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in the last session and the average volume of the stock … Continue reading Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 0.32% in last session and finished the day at $6.20. Traded volume was 4.92million shares in the last session and the average volume of the stock remained 5.60million shares. The beta … Continue reading Healthcare Watch List: Arena Pharmaceuticals (NASDAQ:ARNA), Abbott Laboratories (NYSE:ABT), UnitedHealth Group (NYSE:UNH), AstraZeneca (NYSE:AZN)

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock … Continue reading Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of the stock on the open market in a transaction dated Monday, April 14th. The shares were sold at an average price of $6.22, for a total value of $217,700.00. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 3.25% in last session and finished the day at $6.35. Traded volume was 6.98million shares in the … Continue reading Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA), Zeltiq Aesthetics (NASDAQ:ZLTQ), Entravision Communication (NYSE:EVC), RetailMeNot Inc (NASDAQ:SALE)